Intraventricular treatment of secondary central nervous system lymphoma - Case study and literature overview

Dariusz Szczepanek; Ewa Wąsik-Szczepanek; Agnieszka Szymczyk; Tomasz Gromek; Ewelina Grywalska; Monika Podhorecka; Marek Hus

doi:10.1016/j.pjnns.2018.01.007

Intraventricular treatment of secondary central nervous system lymphoma - Case study and literature overview

Neurol Neurochir Pol. 2018 May-Jun;52(3):410-414. doi: 10.1016/j.pjnns.2018.01.007. Epub 2018 Feb 6.

Authors

Dariusz Szczepanek¹, Ewa Wąsik-Szczepanek², Agnieszka Szymczyk³, Tomasz Gromek², Ewelina Grywalska⁴, Monika Podhorecka², Marek Hus²

Affiliations

¹ Chair and Department of Neurosurgery and Paediatric Neurosurgery Medical University of Lublin, Poland.
² Chair and Department of Haematooncology and Bone Marrow Transplantation Medical University of Lublin, Poland.
³ Chair and Department of Haematooncology and Bone Marrow Transplantation Medical University of Lublin, Poland; Independent Clinical Transplantology Unit Medical University of Lublin, Poland. Electronic address: [email protected].
⁴ Chair and Department of Clinical Immunology Medical University of Lublin, Poland.

PMID: 29703403
DOI: 10.1016/j.pjnns.2018.01.007

Abstract

Secondary nervous system lymphoma (SCNSL) is a rare extranodal form of non-Hodgkin lymphoma (NHL). This applies to a particular form of lymphoma that does not originally derive from the central nervous system (CNS); it can be both an isolated form of relapse or a systemic part of disease progression. Due to poor prognosis and a lack of established algorithms of therapeutic procedures, it is a big challenge for physicians from many specializations. In our study, we present an interesting case of a patient with a relapsed form of SCNSL for whom a unique form of treatment was used - intraventricular administration of rituximab and methotrexate.

Keywords: Intraventricular treatment; Ommaya reservoir; Primary central nervous system lymphomas; Secondary central nervous system lymphomas.

MeSH terms

Central Nervous System Neoplasms*
Humans
Lymphoma, Non-Hodgkin*
Neoplasm Recurrence, Local